中文简体
中文繁体
English
العربية
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
13
2021-08
IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in Molecular Therapy
02
2021-08
IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials
16
2021-06
IASO Bio Appoints Dr. David He as Chief Technology Officer and Executive Vice President
08
2021-06
IASO Biotherapeutics and Innovent Biologics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress
03
2021-06
Clinical trial results of the BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent commented in American Society of Hematology’s medical journal “Blood”
01
2021-06
Application for clinical trial of the 2nd indication of IASO Biotherapeutics’ fully human CD19/CD22 dual-targeted CAR-T drug accepted by NMPA
01
2021-06
Application for clinical trial of the 2nd indication of IASO Biotherapeutics’ fully human CD19/CD22 dual-targeted CAR-T drug accepted by NMPA
23
2021-05
IASO Announced Acceptance of IND Application by NMPA for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy
23
2021-02
The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma
21
2020-12
IASO BIO’s Cell Therapy Summit Forum Successfully Held in Nanjing
<
5
6
7
8
9
>
